Key result
Uninterrupted anticoagulation during atrial flutter ablation yields no major complications with ~8% minor hematomas.
Why the study?
The safety of performing common atrial flutter catheter ablation without discontinuing oral anticoagulation was uncertain.
Cohort (n=102)
Small observational cohort in flutter ablation; leaves open whether uninterrupted OAC raises thromboembolic or bleeding risk.
Aim: To determine if performing catheter ablation under oral anticoagulation is associated with a higher risk of thromboembolic or bleeding complications. Methods: Patients with common atrial flutter that underwent catheter ablation of the cavo-tricuspid isthmus were consecutively included in the study. All patients were taking oral anticoagulants at least 3 weeks before the ablation. Results: A total of 102 patients (mean age 67.9 ± 10.3 years; 83.3% male) were included. Among them 80.6% patients were taking acenocoumarol, 10.7% dabigatran, 7.8% rivaroxaban and 0.9% apixaban. After the procedure, no new pericardial effusion or major complications were detected. In the study 7.8% of patients had mild hematoma in the puncture site. Conclusion: Performing common atrial flutter catheter ablation under oral anticoagulation is associated with low risk of complications.
No takes yet. Share an insight, caveat, or question.
Escobar et al. (2017) conducted a cohort in Common atrial flutter (n=102). Catheter ablation under uninterrupted oral anticoagulation was evaluated on Thromboembolic or bleeding complications (major complications and pericardial effusion). Catheter ablation for common atrial flutter performed under uninterrupted oral anticoagulation resulted in no major complications and a 7.8% rate of mild puncture site hematomas.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: